United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp EVP & General Counsel Paul A. Mahon exercised stock options and sold the resulting shares in a pre-planned transaction. He exercised options for 8,300 shares of common stock at an exercise price of $146.03 per share and received 8,300 shares.
On the same date, he sold 8,300 shares of common stock in multiple open-market trades at weighted average prices generally around the mid-$560s per share, pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. After these transactions, he directly owns 45,172 shares of UNITED THERAPEUTICS common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options for common stock at $146.03 per share and sold the resulting 9,500 shares in multiple open-market trades on April 1, 2026. The reported sale prices ranged from about the high $570s to high $590s per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 shares of common stock directly, plus indirect interests in shares held by her spouse and various family trusts. The plan permits exercise of up to 1,734,410 stock options that expire on March 17, 2027, and continues until those are exercised or December 31, 2026, whichever comes first.
United Therapeutics Chairperson and CEO Martine Rothblatt reported several insider transactions. On March 31, 2026, she exercised stock options to acquire 9,500 shares of Common Stock at an exercise price of $146.03 per share and sold the same 9,500 shares in multiple open-market trades at prices ranging from about $574.55 to $594.18 under a pre-arranged Rule 10b5-1 trading plan.
Following these trades, she directly holds 40,513 shares of Common Stock and stock options for 150,808 shares at an exercise price of $135.42 expiring in March 2027. In addition, family trusts associated with her made bona fide gifts totaling 1,698,384 stock options with exercise prices of $135.42 and $117.76, with no funds exchanged and no sale of shares in connection with these gifts.
Paul Mahon submitted Form 144 notices reporting proposed sales and a stock option exercise involving 8,300 shares. The filing lists multiple past sales of 8,300 shares on 01/15/2026, 02/05/2026, 02/19/2026, 03/05/2026, and 03/19/2026 with dollar amounts shown. The entry for 04/02/2026 is labeled Stock Option Exercise with Cash and Issuer indicated.
United Therapeutics (UTHR) reported insider transactions: a 199,500-share option exercise and multiple pre-arranged 10b5-1 sales. The option exercise was recorded for 04/01/2026 as a cash exercise to the issuer for 199,500 shares. The filing lists repeated 10b5-1 dispositions of 9,500 shares on multiple dates in March 2026 with individual proceeds shown (for example, $5,564,709.55 on 03/31/2026). Shares outstanding are shown as 118,299,510 as of 04/01/2026 in the excerpt.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold the resulting shares under a pre-arranged trading plan. On March 30, 2026, she exercised options to acquire 9,500 shares of common stock at an exercise price of $146.03 per share, converting a derivative position into common stock.
That same day she sold 9,500 common shares in multiple open-market transactions at prices generally around $581–$603 per share, as part of a Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she held 40,513 common shares directly, in addition to indirect holdings reported as held by her spouse and various family trusts.
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share, then sold 10,000 shares in a series of open-market trades at prices generally around $582–$607 per share.
After these transactions, he directly owns 18,876 shares of common stock and holds 132,500 stock options. The exercise and subsequent sales were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025, indicating the trades were scheduled in advance.
UNITED THERAPEUTICS Corp director Christopher Causey exercised stock options and sold shares in a pre-planned transaction. He exercised options for 1,300 shares of Common Stock at an exercise price of $119.76 per share and then sold 1,300 shares at $604.64 per share on the same date. These moves were executed under a Rule 10b5-1 trading plan entered into on September 30, 2025, indicating the trades were scheduled in advance. Following the transactions, he directly held 4,190 shares of Common Stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and acquired the underlying shares. She then sold 9,500 common shares in multiple open-market transactions on March 27, 2026 at prices generally above $522 per share, with trades executed in ranges described in the filing.
These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the transactions, Rothblatt holds 40,513 common shares directly and also reports additional indirect holdings through her spouse and various family trusts.
United Therapeutics Corporation submitted a Form 144 notice to sell 1,300 shares of Common Stock via a stock option exercise to be effected on 03/30/2026. The filing lists prior open-market dispositions by Christopher Causey totaling multiple transactions in January–March 2026.